Mazen Khalil, MD
Hematology & Oncology · Jonesboro, ARNPI 1659323608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 979 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.3% — the pattern of someone who eats at a lot of different presentations.
Across 979 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Merck$1K
- Pfizer$1K
- Novartis$1K
- Johnson & Johnson$873
- E.r. Squibb & Sons, L.L.C.$860
- plus $11K from 54 others
Across 98 payments — averaging $19,867 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$732K
- Merck$407K
- Eli Lilly$291K
- AstraZeneca$196K
- E.r. Squibb & Sons, L.L.C.$148K
- Amgen$102K
- plus $71K from 5 others
What the payments were for
- Food & beverage$17,31097%
- Education$4913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,801 in reported general payments places this provider in the 80th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 43 | $693,174 |
| VerzenioAbemaciclib | 45 | $684,574 |
| CabometyxCabozantinib S-Malate | 23 | $568,564 |
| XtandiEnzalutamide | 38 | $512,738 |
| BrukinsaZanubrutinib | 34 | $483,566 |
| LenvimaLenvatinib Mesylate | 18 | $408,565 |
| IbrancePalbociclib | 27 | $405,757 |
| JakafiRuxolitinib Phosphate | 22 | $394,059 |
| RevlimidLenalidomide | 25 | $366,805 |
| PromactaEltrombopag Olamine | 30 | $284,585 |
| Lenalidomide | 27 | $248,260 |
| Abiraterone Acetate | 70 | $233,664 |
| Somatuline DepotLanreotide Acetate | 25 | $228,906 |
| TasignaNilotinib Hcl | 16 | $150,069 |
| IressaGefitinib | 14 | $98,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $184 | $693,17443 claims |
| Lilly USA, LLCVerzenio | $212 | $684,57445 claims |
| Exelixis Inc.Cabometyx | $270 | $568,56423 claims |
| NovartisPromacta, Tasigna, Sandostatin Lar Depot | $1,101 | $518,10859 claims |
| Astellas Pharma US IncXtandi | $145 | $512,73838 claims |
| Beigene USA, Inc.Brukinsa | $183 | $483,56634 claims |
| PfizerIbrance, Eliquis | $1,142 | $416,72946 claims |
| Eisai Inc.Lenvima | $533 | $408,56518 claims |
| Incyte CorporationJakafi | $293 | $394,05922 claims |
| Bristol Myers SquibbRevlimid | $313 | $366,80525 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $188 | $228,90625 claims |
| AstraZenecaIressa | $1,483 | $98,76614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Jonesboro
- Carroll ScrogginJonesboro$7K
- Scott DorrohJonesboro$6K
- David NixonJonesboro$2K
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
- Isam Abdel-KarimFort Smith$199K
- Appalanaidu SasapuLittle Rock$63K
- Stephan RosenfeldFayetteville$61K
- Stephen DiversHot Springs$55K
- Humdum DurraniFort Smith$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.